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Abstract
Glucose restriction (GR) impairs muscle cell differentiation and evokes myotube atrophy. Resveratrol treatment in skeletal 
muscle cells improves inflammatory-induced reductions in skeletal muscle cell differentiation. We therefore hypothesised 
that resveratrol treatment would improve muscle cell differentiation and myotube hypertrophy in differentiating C2C12 
myoblasts and mature myotubes during GR. Glucose restriction at 0.6 g/L (3.3 mM) blocked differentiation and myotube 
hypertrophy versus high-glucose (4.5 g/L or 25 mM) differentiation media (DM) conditions universally used for myoblast 
culture. Resveratrol (10 µM) treatment increased SIRT1 phosphorylation in DM conditions, yet did not improve differentiation 
when administered to differentiating myoblasts in GR conditions. Resveratrol did evoke increases in hypertrophy of mature 
myotubes under DM conditions with corresponding elevated Igf-I and Myhc7 gene expression, coding for the ‘slow’ type I 
MYHC protein isoform. Inhibition of SIRT1 via EX-527 administration (100 nM) also reduced myotube diameter and area 
in DM conditions and resulted in lower gene expression of Myhc 1, 2 and 4 coding for ‘intermediate’ and ‘faster’ IIx, IIa 
and IIb protein isoforms, respectively. Resveratrol treatment did not appear to modulate phosphorylation of energy-sensing 
protein AMPK or protein translation initiator P70S6K. Importantly, in mature myotubes, resveratrol treatment was able to 
ameliorate reduced myotube growth in GR conditions over an acute 24-h period, but not over 48–72 h. Overall, resveratrol 
evoked myotube hypertrophy in DM conditions while favouring ‘slower’ Myhc gene expression and acutely ameliorated 
impaired myotube growth observed during glucose restriction.
Keywords SIRT1 · Dietary restriction · Myoblasts · Hypertrophy · Atrophy · MYHC · P70S6K · AMPK · MYHC
Introduction
Calorie Restriction (CR) promotes improvements in 
lifespan and healthspan in mammalian organisms due to 
chronic reductions in Insulin/Insulin-like-Growth-Factor-I 
(IGF-I) signalling, inflammation, DNA damage and oxida-
tive stress (reviewed in [1]). However, reductions in IGF-I 
and downstream IGF-IR/protein kinase B (AKT)/mTOR/
P70S6K negatively affect skeletal muscle mass via reduc-
tions in protein synthesis [2–6], muscle cell proliferation, 
differentiation and survival [7, 8]. In skeletal muscle, calo-
rie restriction results in reduced IGF-I levels, a threefold 
reduction in Akt mRNA and 30–50% reduction in Akt pro-
tein activity, with corresponding increases in FoxO3a gene 
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expression [9], leading to transcription of muscle-specific 
ubiquitin ligases/atrogenes MuRF-1 and MAFbx that ‘tag’ 
cytoskeletal and myofibrillar proteins for degradation in the 
proteasome [10–12]. Therefore, during CR a paradox exists 
where an attempt by the organism to improve longevity via 
reductions in IGF signalling are potentially at the expense 
of a loss in skeletal muscle regenerative capacity and mass 
(reviewed in [1]). As a consequence, using pharmacologi-
cal or naturally derived agents that maintain muscle while 
calorie restricted would potentially be advantageous to 
improve health/lifespan while reducing the loss of muscle 
mass. Research into the activation of the Sirtuins (SIRT1-
7), a group of protein deacetylases involved in the process 
of chromatin remodelling and gene regulation (see [13], by 
a naturally occurring polyphenol resveratrol (contained in 
the skin of red grapes), has provided some insights into the 
Sirtuins’ potential in both enabling improved healthspan and 
maintaining muscle cell regenerative function.
Indeed these insights suggest that reductions in SIRT1 
activity in skeletal muscle occur following acute fasting in 
mice, with a corresponding increase in protein degradative 
MuRF-1 and MAFbx and reductions in muscle mass [14]. 
Our group has also shown that the induction of apoptosis 
and inhibition of differentiation in murine skeletal muscle 
cells by high-dose inflammatory cytokine, Tumour Necrosis 
Factor-alpha (TNF-α), was associated with increased SIRT1 
mRNA levels, which when suppressed using silencing RNA 
resulted in exacerbated apoptosis [15, 16]. Importantly, the 
Sirtuin activator resveratrol was able to attenuate apoptosis 
and improve differentiation back towards baseline levels, 
suggesting that Sirtuin activation was important to survival 
and differentiation of skeletal muscle cells under a catabolic 
inflammatory stress. More recent studies have confirmed 
these findings, where resveratrol was also able to reverse 
impairments protein activity of Akt, mTOR, P70S6K and 
4E-BP1 following TNF-α treatments in C2C12 cells [17]. It 
has also been demonstrated that resveratrol can reduce age-
related ill health in ad libitum fed aged mice if administered 
from mid-age, albeit without impact on lifespan [18, 19], 
and can extend lifespan when mice are placed under nutri-
ent stress from a high fat diet [20]. Therefore, resveratrol 
has the potential to reduce the impact of metabolic stress 
while helping maintain appropriate muscle cell function for 
skeletal muscle maintenance and regener ation.
Due to the requirement for adequate SIRT1 activation 
in muscle cell survival in vitro [16], an identified role for 
SIRT1 activation in regeneration/differentiation during 
inflammation in vitro and nutrient stress in vivo [20], we 
aimed to investigate whether Sirtuin activation via resvera-
trol treatment in skeletal muscle cells would attenuate loss of 
differentiation and myotube hypertrophy in both regenerat-
ing myoblasts and existing mature myotube cultures while 
modelling CR conditions in vitro. Reducing carbohydrate 
and glucose intake is a common approach when undertaking 
CR (reviewed in [21]). Therefore, glucose restriction (GR) 
has been used to model CR in vitro in cell types such as 
yeast [22], fibroblasts [23] and kidney cells [24]. In muscle 
cells, previous studies have used low glucose concentra-
tions in vitro in an attempt to mimic circulatory glucose 
levels experienced during CR in vivo [25, 26]. However, 
the amount of glucose that muscle cells would actually be 
exposed to in the interstitial space during CR has not yet 
been modelled in vitro. The previously reported values for 
blood glucose during CR are 0.74 g/L (4.1 mM) in humans 
[27] and 1 g/L (5.6 mM) in murine models [28]. Glucose 
values in the muscle interstitial space have been reported to 
be 30% lower than those found in the blood of both rodents 
[29] and humans [30]. Therefore, applying the aforemen-
tioned 30% reduction would estimate glucose in the inter-
stitial space at between 0.5 and 0.7 g/L (2.8 and 3.9 mM) for 
humans and rodents, respectively. Therefore, in the present 
study, we used 0.6 g/L of glucose in vitro to model intersti-
tial glucose levels under CR in vivo. Both differentiating 
C2C12 myoblasts and mature myotubes were then investi-
gated over time in GR conditions in the absence or presence 
of Sirtuin activator resveratrol and SIRT1 inhibitor, EX-527. 
These conditions were compared to conditions of 4.5 g/L 
(25 mM) high-glucose differentiation (DM) media that is 
universally and routinely used for both proliferating and dif-
ferentiating skeletal muscle cells in vitro, with high-glucose 
DMEM used extensively in studies investigating the effect 
of resveratrol in C2C12 myoblasts [17, 31–34]. Overall, we 
hypothesised that (1) resveratrol treatment would help pre-
serve differentiation and myotube hypertrophy in differen-
tiating myoblasts under glucose restriction, and (2) resvera-
trol would improve myotube survival and prevent myotube 
atrophy in mature differentiated myotubes following glucose 
restriction (GR).
Methods
Cell culture
C2C12 murine myoblasts [35] between passage 8 and 10 
were incubated in separate T75 flasks in a humidified envi-
ronment (37 °C, 5%  CO2) with growth media (GM) contain-
ing Dulbecco’s Modified Eagle Serum (DMEM) (D6429, 
Sigma-Aldrich, UK), 1% Penicillin Streptomycin (Pen-
strep), 10% New born calf serum (NBCS) and 10% Foetal 
Bovine Serum (FBS) until 80% confluency was attained. 
Cells were trypsinized and cell counts were preformed using 
a haemocytometer in the presence of Trypan Blue dye. For 
studies in differentiating myoblasts, 6-well plates were pre-
treated with 0.2% porcine gelatin for 10 min at room tem-
perature (RT) and 10 min in a humidified, 37 °C/5%  CO2 
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environment. The excess gelatin was aspirated and cells were 
seeded at 8 × 104 cells/ml in 2 ml of GM per well, these were 
then incubated for 24 h until 80% confluency was attained. 
Experiments were initiated by removing GM, washing twice 
with phosphate buffered saline (PBS) followed by the addi-
tion of low serum differentiation media for a total period 
of 7 days, containing: 8.3 g/L of DMEM (D5030, Sigma-
Aldrich, UK), 0.584  g/L l-Glutamine, 3.7  g/L Sodium 
Bicarbonate, 0.11 g/L Sodium Pyruvate, 0.0159 g/L Phenol 
red, 2% horse serum and 1% Pen-strep and either 0.6 g/L or 
3.3 mM (glucose restricted/GR) or 4.5 g/L (25 mM) high-
glucose differentiation medium (DM) universally used for 
myoblast proliferation and differentiation and used exten-
sively in previous studies assessing the role of resveratrol 
in C2C12 cells [17, 31–34], whilst also allowing relevant 
comparisons with the existing literature. The reduction in 
serum content causes  C2C12 myoblasts to undergo spon-
taneous differentiation without requiring the addition of 
growth factors to initiate the process [35]. Time point zero 
was defined as an incubation of 30 min after transfer to DM 
and is denoted as 0 h (0 h). To assess the effect of resvera-
trol treatment and SIRT1 inhibition in myoblasts that were 
glucose restricted (GR) versus high-glucose differentiation 
media (DM), cells were incubated in either 0.6 g/L / 3.3 mM 
(GR) versus 4.5 g/L / 25 mM (DM) in the absence or pres-
ence of resveratrol (RES) at a concentration of 10 µM and 
SIRT1 inhibitor (EX-527) at 100 nM. Morphological analy-
sis (myotube number, diameter and area), creatine kinase 
assays, and RNA extraction/ isolation for gene expression of 
genes associated with muscle cell differentiation (myogenin) 
and myotube maturation (Myhc 1, 2, 4, 7) were conducted 
at 0, 72 h and 7 days.
For studies in differentiated myotubes, myoblasts at pas-
sages 12–15 were washed in PBS and transferred into 2 ml 
of DM in 37 °C at 5%  CO2 for 7 days in order to differenti-
ate. Once myotubes had been formed over 7 days, cells were 
dosed in the below experimental conditions for a further 
72 h (total time 10 days in culture) to assess the impact of 
resveratrol and EX-527 treatment during glucose restriction 
(GR) conditions in existing myotubes: GR differentiation 
media (0.6 g/L / 3.3 mM glucose alone), High-glucose dif-
ferentiation media (DM) (4.5 g/L glucose alone), GR + Res-
veratrol (RES) (0.6 g/L glucose + 10 μM RES), DM + RES 
(4.5 g/L glucose + 10 μM RES), GR + EX-527 (0.6 g/L 
glucose + 100 nM EX-527) and DM + EX-527 (4.5 g/L glu-
cose + 100 nM EX-527). Resveratrol/EX-527 was purchased 
from Merck Millipore (cat no 554325/566322, respectively, 
Nottingham, UK). Resveratrol was manufactured by Cal-
biochem (cat no CAS 501-36-0, San Diego, CA, USA). 
Resveratrol/EX-527 was reconstituted in DMSO and this 
stock was stored in -20 °C for up to three/six months, respec-
tively, according to the manufacturer’s instructions. Mor-
phological analysis of myotube number, diameter and area 
were performed 24, 48 and 72 h. For these experiments, 
the 0 h (0 h) baseline control condition was 7 days in DM 
to promote myotube formation, after which time cells were 
washed × 2 in PBS and then placed in fresh DM for 30 min 
containing (denoted DM 0 h). Protein activity of AMPK 
and P70S6K was analysed from protein lysates extracted 
at 0-, 15- and 30-min, 2- and 24-h time points after dosing 
occurred in myotubes in order to investigate energy sensing 
vs. protein synthetic/growth-associated cellular signalling 
following resveratrol and EX-527 administration in exist-
ing myotubes in GR versus DM glucose conditions. Gene 
expression for later differentiation and myotube maturation 
(Mrf4, Myhc1, 2, 4, 7) and genes associated with myotube 
hypertrophy (Igf-I, Igf-Ir, Igf-II, Igf-IIr, Igfbp2, Mtor), myo-
tube atrophy (Tnf-α, Tnfrsflb, Myostatin, Mur1f, Mafbx, 
Musa1, Fox01, 3, Nf-kb, p53) as well as Sirt1 gene expres-
sion were completed at 0, 24 and 72 h.
Morphology to assess differentiation and myotube 
hypertrophy/atrophy
Myotube parameters including number, diameter and area 
were assessed using a live imaging light microscope (AF600 
modular system, Leica, Germany) cell imaging system 
at ×10 or ×20 magnifications (see figure legends for details). 
Per experiment, each time point and experimental condition 
was imaged in duplicate with six images taken per well pro-
viding a total of 12 images per condition per time point per 
n. Experiments were then repeated n = 3. Automated mark 
and find on the Leica AF600 microscope allowed six images 
per well to be taken in the same position between conditions 
automatically, with the 6 locations chosen equally spread 
around the well. Analysis of myotube number, diameter and 
area was performed on the images using ImageJ software 
((National Institutes of Health, USA) as previously defined 
in [36–38].
Creatine kinase assay
Cells were extracted for total protein assays and CK (creatine 
kinase) activity (a biochemical marker of myoblast differ-
entiation) at 0, 72 and 7 days in differentiating C2C12 myo-
blasts. Briefly, cells were washed twice in PBS and lysed in 
250 µl well−1 of 0.05 M Tris/MES Triton lysis buffer (TMT: 
50 mM Tris-MES, pH 7.8, 1% Triton X-100) and assayed 
using commercially available  BCA™ (Pierce, Rockford, IL, 
U.S.A) and CK activity (Catachem Inc., Connecticut, N.E, 
USA) assay kits according to the manufacturer’s instruc-
tions. The enzymatic activity for CK was normalised to total 
protein content. CK and total protein were determined using 
a  CLARIOstar® plate reader (BMG labtech, Germany) at a 
wave length of 340 nm and 540–590 nm, respectively.
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RNA isolation and quantification
RNA isolation was performed using the TRIzol method, 
following the manufacturer’s instructions (Invitrogen, Life 
technologies, Carlsbad, CA). RNA purity and concentration 
were assessed using 1 μl of sample on a NanoDrop 2000c, 
UV–Vis (Ultraviolet–Visible spectroscopy) spectrophotom-
eter (Thermo Fisher Scientific, MA, USA) using ODs of 230, 
260 and 280 nm. A ratio of these OD value was calculated for 
each sample with all samples possessing 260/280 ratios of 
between 1.8 and 2.2 and therefore accepted as high enough 
quality RNA to enable downstream RT-PCR analysis.
Primer design
Primer sequences (Table 1) were identified using Gene 
(NCBI, http://www.ncbi.nlm.nih.gov/gene) and designed 
using both web-based OligoPerfectTM Designer (Invitro-
gen, Carlsbad, CA, USA) and Primer-BLAST (NCBI, http://
www.ncbi.nlm.nih.gov/tools/primer-blast), with the excep-
tion of IGF-I mature peptide mRNA primers that were used 
in [39]. Primers were purchased from Sigma (Suffolk, UK) 
without the requirement of further purification. Sequence 
homology (BLAST) searches ensured specificity to ensure 
the primers matched the sequence and therefore gene that 
they were designed for. Three or more GC bases in the 
last five bases at the 3′ end of the primer were avoided as 
stronger bonding of G and C bases can cause non-specific 
amplification. Primer sequences were designed to exclude 
hairpins, self-dimer and cross-dimers. All primers details 
can be found in Table 1.
Gene expression by rt‑qRT‑PCR
Rt-qRT-PCR was carried out using Quantifast SYBR green 
RT-PCR kit (Qiagen, Manchester, UK) on a Rotor-Gene® 
(Qiagen, Manchester, UK) supported by Rotor-Gene® Q 
Software, version 2.1.0.9 (Qiagen, Manchester, UK). The 
rt-qRT-PCR cycles consisted of the following: 48  °C, 
30 min (reverse transcription/ cDNA synthesis); 95 °C, 
10 min (transcriptase inactivation and initial denaturation) 
followed by 40 cycles of 95 °C, 15 s (denaturation); 60 °C, 
1 min (annealing and extension in 1 step). Disassociation 
melt-curve analysis was performed to reveal and therefore 
exclude non-specific amplification and primer dimer issues. 
All our gene products yielded a single melt peak/tempera-
ture suggesting that one product was amplified. Relative 
gene expression analysis was carried out using ΔΔCt equa-
tion, otherwise known as the Livak method [40], this was 
to establish normalised expression ratios, where the relative 
expression was calculated as  2−ΔΔCt and  Ct represents the 
cycle threshold. RT-PCR efficiency was similar across RT-
PCR runs and conditions (90.99 ± 2.28%, variation 2.48%). 
Polr2ß (a.k.a Rp-IIb) was also extremely stable between 
experimental conditions (mean  Ct 15.62 ± 0.11) and there-
fore used as the reference gene in all RT-PCR assays and 
the pooled mean used in the ΔΔCt calculations. All rt-qRT-
PCR figures are presented as a relative gene expression 
in comparison to the 0 h cells incubated in DM glucose 
(4.5 g/L / 25 mM). This 0 h sample was used as a calibrator 
condition in the subsequent equations in order to compare 
expression values across glucose concentrations.
SDS‑PAGE and western blotting
Cells were lysed in 300 µl lysis buffer per well of a 6-well 
plate, including phosphatase inhibitors (10 mM TrisHCL, 
5 mM EDTA, 50 mM Sodium Chloride, 30 mM Sodium 
Pyrophosphate, 50 mM Sodium Fluoride, 100 μM Sodium 
Orthovanadate, 1 mM PMSF and 1% Triton X-100.) sup-
plemented with protease inhibitor tablets as per the manu-
facturer’s instructions (Roche, Switzerland). Following 
analysis of total protein via BCA assay as above, 30 µg 
of protein was reconstituted in 1:5 dilution with 5X Lae-
mmli buffer (3 ml 1M TRIS–HCl (pH 6.8.), 1 g Sodium 
dodecyl sulphate, 5 ml glycerol, 1 ml  DH2O and 25 mg 
Bromophenol blue). Ten percent resolving SDS-Poly-
acrylamide (SDS-Page) gels (4 ml 30% acrylamide 1% 
BIS solution, 3.4 ml  DH2O, 2.5 ml 1.5M Tris Base, 100 μl 
10% SDS, 50 μl 10% APS and 5 μl TEMED) were poured, 
and a layer of butanol was then syringed across the top 
of the resolving solution and cast for 30 min. Following 
butanol removal, a 5% stacking gel solution (1.7 ml 30% 
acrylamide 1% BIS solution, 5.7 ml  DH2O, 2.5 ml 0.5M 
Tris Base, 100 μl 10% SDS, 50 μl 10% APS and 10 μl 
TEMED) was poured and a lane comb inserted. These gels 
were run at 200 V in a Mini-  PROTEAN® Tetra vertical 
electrophoresis cell (Bio-Rad Laboratories, Inc. CA, USA) 
until the bromophenol blue dye line reached the bottom of 
the gel (approximately 1 h). The protein was then trans-
ferred for 30 min at 200 V onto a nitrocellulose membrane 
within a semi-dry Trans-blot®  Turbo™ Blotting system cas-
sette (Bio-Rad Laboratories, Inc. CA, USA) using trans-
fer buffer (20 ml 10 × Tris Glycine, 40 ml methanol and 
140 ml  DH2O). The nitrocellulose membrane was prepared 
for detection of specific phosphorylated and total proteins 
using a  Pierce™ Fast Western Kit, Supersignal West Pico 
(Rabbit) (Thermofisher scientific, MA, USA) as per the 
manufacturer’s instructions including timings for incuba-
tion, with the following primary antibodies (all raised in 
rabbit) purchased from Cell Signalling Technology, MA, 
USA unless otherwise stated: Phospho AMPK 1:1000 
(cat no: #2535), total AMPK 1:1000 (#2532), phospho 
P70S6K 1:1000 (#9205), total P70S6K 1:1000 (#9202), 
phospho SIRT1 1:2000 (#2314L) and total SIRT 1:2000 
(Millipore, Watford, UK cat no: #07-131). Incubation with 
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the secondary rabbit HRP antibody, was also provided in 
the above  Pierce™ Fast Western Kit and applied as per the 
manufacturer’s instructions. Enhanced chemilluminescence 
(ECL) detection reagents as provided by the  Pierce™ Fast 
Western Kit described above were used in a 1:1 dilution 
and incubated over the membrane for 5 min. The membrane 
Table 1  Primer details for gene 
expression analysis Gene Primer Sequence (5′-3′) Reference number Amplicon length (bp)
MyoD F: CAT TCC AAC CCA CAG AAC 
R: GGC GAT AGA AGC TCC ATA 
NM_010866.2 125
Mrf4 (Myf6) F: GGC TCT CCT TTG TAT CCA GGG
R: CGA TCT GTG GGG GCA GAT TT
NM_008657.2 194
Myogenin F: CCA ACT GAG ATT GTC TGT C
R: GGT GTT AGC CTT ATG TGA AT
NM_031189.2 173
Myhc1 F: CGG TCG AAG TTG CAT CCC TA
R: TTC TGA GCC TCG ATT CGC TC
NM_030679.1 149
Myhc2 F: GCG AAG AGT AAG GCT GTC CC
R: GGC GCA TGA CCA AAG GTT TC
NM_001039545.2 76
Myhc4 F: AGG AGG CTG AGG AAC AAT CC
R: TTC TCC TGT CAC CTC TCA ACA
NM_010855.3 192
Myhc7 F: TGT GCT ACC CAG CTC CAA G
R: CTG CTT CCA CCT AAA GGG CTG
NM_080728.2 77
Musa1 F: CCT TGA GGC TCC CGG CAA AT
R: ACT GCT CCA CAA ACC AAT GGA
NM_001168297.1 189
Sirt1 F: ACA ATT CCT CCA CCT GAG 
R: GTA ACT TCA CAG CAT CTT CAA
NM_019812.3 124
Myostatin F: TAC TCC AGA ATA GAA GCC ATAA
R: GTA GCG TGA TAA TCG TCA TC
NM_010834.3 194
Igf-I F: GCT TGC TCA CCT TTA CCA GC
R: TTG GGC ATG TCA GTG TGG 
NM_010512.5 280
Igf-Ir F: TGC GGT GTC CAA TAA CTA C
R: TGT TGA TGG TGG TCT TCT C
NM_010513.2 110
Igf-II F: GTA CAA TAT CTG GCC CGC CC
R: GTA TGC AAA CCG AAC AGC GG
NM_010514.3 188
Igf-IIr F: GGA ACT CCT GAA TTT GTA ACT
R: CTA CCA GAT AGC CAC CAT T
NM_010515.2 181
Igfbp2 F: AGT GCC ATC TCT TCT ACA A
R: GCT CAG TGT TGG TCT CTT 
NM_008342.3 197
Mtor F: CAC TCC ACT ATC CTG TTA CCT
R: GAG ATC CTT GGC ACA CCT 
NM_020009.2 190
Murf1 F: CCA AGG AGA ATA GCC ACC AG
R: CGC TCT TCT TCT CGT CCA G
NM_001039048.2 84
Mafbx F: GTC GCA GCC AAG AAG AGA A
R: CGA GAA GTC CAG TCT GTT GAA
NM_026346.3 156
FoxO1 F: AGT GGA TGG TGA AGA GCG TG
R: GAA GGG ACA GAT TGT GGC GA
NM_019739.3 96
FoxO3 F: CGG ACA AAC GGC TCA CTT T
R: TCG GCT CTT GGT GTA CTT G
NM_019740.2 272
Tnf-α F: TCA ACA ACT ACT CAG AAA CAC
R: AGA ACT CAG GAA TGG ACA T
NM_013693.3 130
Tnfrsf1b F: GTT GCT CTG TTA TAG GAT GGT
R: TGC TGT CTG CTG TCT ACT 
NM_011610.3 114
Nf-κβ F: ACA CGA GGC TAC AAC TCT GC
R: GGT ACC CCC AGA GAC CTC AT
NM_008689.2 164
p53 F: CAT CCT GGC TGT AGG TAG CG
R: GGC AGT CAT CCA GTC TTC GG
NM_011640.3 109
RpIIb (a.k.a: pol2rb) F: GGT CAG AAG GGA ACT TGT GGTAT
R: GCA TCA TTA AAT GGA GTA GCGTC
NM_153798.2 197
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was then placed in the  Chemidoc™ MP System (Bio-Rad 
Laboratories, Inc. CA, USA.) where the band images were 
detected by densitometry in which the first image was taken 
at 5 s and intervals of 30.5 s thereafter. Following imaging, 
the band volumes were detected using Image  lab™ (Bio-
Rad Laboratories, Inc. CA, USA.). The bands for the phos-
phorylated protein were relativised to its own total protein 
counterpart before determining changes between experi-
mental groups. GAPDH was detected on all membranes 
prior to further detection. To establish whether loading of 
protein was comparable, we determined the volume values 
for GAPDH (GAPDH concentration 1:4000, Cell Signal-
ling Technology, MA, USA cat no: #5174). In the unlikely 
event that GAPDH was significantly different between con-
ditions, the samples were also relativised to the GAPDH 
loading control.
Statistical analysis
All data analyses were carried out using  Minitab® 17 
(Minitab Ltd, Coventry U.K). Outliers were removed using 
Grubbs outlier test. All data were parametric, assessed using 
the Anderson–Darling test for normality. For statistical anal-
ysis of the dependent variables investigated in differentiating 
myoblasts, a general linear model (2 × 2 × 3) for time (72 h, 
7 days), glucose concentration (GR, DM) and resveratrol/
EX-527 treatment (DM, RES, EX-527) where carried out 
for morphological analysis of myotube number, diameter 
and area. For CK activity and gene expression, a general 
linear model (4 × 2 × 3) for time (0, 24, 72 h, 7 days), glucose 
concentration (GR, DM) and resveratrol/EX-527 treatment 
(DM, RES, EX-527) was conducted. For statistical analy-
sis of the dependent variables investigated in differentiated 
myotubes (already differentiated for 7 days prior to treat-
ments), a general linear model (2 × 2 × 3) for time (0, 72 h), 
glucose concentration (GR, DM) and resveratrol/EX-527 
treatment (DM, RES, EX-527) where carried out for mor-
phological analysis of myotube number, area and diameter 
for the 72-h data. Morphological analysis for the additional 
24-h and 48-h data was also performed subsequently using 
a general linear model (2 × 2 × 3) for time (0, 24 and 48 h), 
glucose concentration (GR, DM) and resveratrol/EX-527 
treatment (DM, RES, EX-527). Gene expression data for 
both the 72-h and 24-h data were performed using a general 
linear model (2 × 2 × 3) for time (0, 72 h or 0, 24 h), glucose 
concentration (GR, DM) and resveratrol/EX-527 treatment 
(DM, RES, EX-527). A general linear model for glucose 
(LOW, NOR) and resveratrol/EX-527 treatment (DM, RES, 
EX-527) was performed for phosphorylated protein activ-
ity. Relevant post hoc corrections tests were performed to 
identify significant comparisons. Statistical significance was 
at the level of p ≤ 0.05.
Results
The effect of resveratrol and glucose restriction 
on myoblast differentiation and myotube 
hypertrophy
SIRT1 is a histone deacetylase and phosphorylation 
of SIRT1 is required to enable increases in deacetylase 
activity [41]. Therefore, in order to first assess the optimal 
dose of resveratrol and EX-527 in C2C12 cells, SIRT1 
phosphorylation was assessed in DM control glucose 
conditions. Indeed, SIRT1 phosphorylation increased on 
average by 15-fold versus DM control when relativised to 
total SIRT1 after 24-h administration of resveratrol. The 
higher dose of 15 µM resveratrol showed no additional 
increase versus 10 µM (where 5 µM resulted in no signifi-
cant increase in SIRT1 phosphorylation) and higher doses 
of 30 and 60 µM of resveratrol were cytotoxic and evoked 
cell death (data not shown) as suggested in previous inde-
pendent studies using these doses in C2C12 cells [33]. 
Following the addition of 100 nM EX-527, we observed 
an average decrease of 71% in SIRT1 phosphorylation fol-
lowing 24 h in comparison to the DM control at 15 min, 
compared to only a 50% reduction after 24 h in SIRT1 
phosphorylation without EX-527 administration. Follow-
ing these initial experiments, we next sought to assess the 
role of glucose restriction alone on myoblast differentia-
tion. Glucose restriction completely blocked differentia-
tion in myoblasts demonstrated by no myotube formation 
in these conditions (Fig. 1a). This corresponded with a sig-
nificant reduction in myogenin gene expression at 72 h ver-
sus DM conditions (GR; 1.48 ± 1.53 vs. DM; 5.62 ± 4.12, 
p = 0.047, Fig. 1b). This was associated with significant 
increases in Sirt1 transcript expression in GR conditions 
at 72 h (GR vs. DM: 2.97 ± 0.84 vs. 0.55 ± 0.23, p ≤ 0.05, 
Fig. 1b), a similar finding to that demonstrated previously 
upon blocking differentiation in the presence of the inflam-
matory cytokine TNF-α [16]. Resveratrol (10 μM) was 
also unable to improve myogenin expression (data not pre-
sented) or prevent the block on morphological differentia-
tion in GR conditions. Despite this, resveratrol improved 
biochemical marker of differentiation, creatine kinase 
(CK), in GR conditions at 7 days (GR: 16.82 ± 15.95 vs. 
GR RES 54.4 ± 44.7 mU mg ml−1, p = 0.069; Fig. 1c), 
albeit not quite attaining statistical significance. How-
ever, changes in CK activity were also temporally delayed, 
where increases are usually observed 48–96 h post serum 
withdrawal in normal glucose conditions [42–44]. Fur-
ther, this non-significant increase in CK activity was 
without improvement in morphological differentiation, 
where CK levels did not approach those observed in DM 
glucose conditions alone (281.5 ± 101.5 mU mg ml−1). 
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Fig. 1  a Glucose Restriction (GR) blocked differentiation in dif-
ferentiating myoblasts with significant reductions in; b myogenin 
and increases in Sirt1 gene expression. Resveratrol improved, c CK 
activity in GR conditions # (albeit non-significantly p = 0.069), with-
out improvements in differentiation. Resveratrol also improved, d, e 
myotube area when glucose was more readily available in DM (dif-
ferentiation media control) conditions at 7  days post induction of 
differentiation. This was associated with increases in f Myhc7 and 
Myhc4 coding for the slow type I and fast IIb MYHC protein iso-
forms. Further, EX-527 administration in DM conditions resulted in 
reductions in g Myhc1 coding for IIx MYHC protein isoform with 
this condition displaying the smallest mean myotube size versus all 
other conditions. *Significantly different (p ≤ 0.05) versus DM condi-
tions. **Significantly, (p ≤ 0.05) different versus EX-527 conditions. 
All experiments are at least n = 3 in duplicate
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Further, resveratrol was unable to improve myotube num-
ber or diameter in DM conditions, however, did signifi-
cantly improve myotube area after 7 days of differentia-
tion versus DM alone and versus EX527 administration 
(DM; 4551 ± 2836 μm2 vs. DM RES; 5718 ± 3532 μm2, 
p = 0.044, vs. DM EX 527; 4142 ± 1873 μm2, p = 0.021, 
Fig.  1d, e), suggesting an increase in myotube length 
versus width. This was associated with a corresponding 
increase in Myhc7 and Myhc4 coding for the slow type 
I and fast IIb MYHC protein isoforms, respectively, in 
resveratrol versus DM alone conditions (Myhc7: DM vs. 
DM RES: 10.53 ± 9.84 vs. 77.5 ± 102.4, p = 0.002, Myhc4: 
DM vs. DM RES: 67.9 ± 19.2 vs. 172.4 ± 111.8, p < 0.001, 
Fig. 1f). Furthermore, EX-527 administration resulted in 
reductions in Myhc1 coding for intermediate IIx MYHC 
protein isoform (DM vs. DM EX527: 212.4 ± 120.4 vs. 
123 ± 124, p = 0.008, Fig. 1g), with this condition display-
ing the smallest mean myotube size (4142 ± 1873 μm2, 
Fig. 1e). Overall, resveratrol treatment in normal glucose 
conditions evoked higher gene expression associated with 
a slow and fast fibre formation and EX-527 administration 
resulted in lower gene expression associated with inter-
mediate fibre formation. However, resveratrol treatment 
was unable to prevent the complete block on differentia-
tion, despite improved CK activity, in glucose-restricted 
conditions.
Resveratrol was unable to prevent reduced 
myotube growth in glucose restriction conditions 
yet improved myotube hypertrophy when glucose 
was available
Since resveratrol induced changes in Myhc gene expression 
were at later time points of differentiation in myoblasts, we 
decided to investigate the role of resveratrol and EX-527 
treatment in both DM and glucose restriction (GR) condi-
tions in existing myotubes (already matured for 7 days). 
Firstly, we confirmed that GR alone evoked a consider-
able reduction in myotube number (DM 9 ± 2.85 vs. GR 
5.38 ± 2.28, p ≤ 0.05, Fig. 2a, b), and reduced myotube 
growth demonstrated by reductions in myotube diam-
eter (DM 15.56 ± 5.38 vs. GR 12.1 ± 4.453 μm, p ≤ 0.05, 
Fig. 2a, c) and area (DM 3820 ± 2625 vs. GR 2897 ± 2024 
μm2, p ≤ 0.05, Fig. 2 a, d) in existing myotubes after 72-h 
glucose restriction. These morphological observations 
were confirmed in GR alone versus DM conditions, where 
lower gene expression of myotube maturation genes Myhc1, 
2, 4, 7 (Myhc1: DM 3.2 ± 0.4 vs. GR 1.2 ± 0.29; Myhc2: 
1.86 ± 0.28 vs. GR 0.39 ± 0.13; Myhc4: DM 4.19 ± 1.87 vs. 
GR 0.92 ± 0.31; Myhc7: DM 4.32 ± 1.39 vs. GR 1.06 ± 0.3, 
all p ≤ 0.05, Fig. 2e), and genes associated with myotube 
hypertrophy were observed (Igf-I; Igf-Ir and Igfbp2 (Igf-I: 
DM 1.59 ± 0.32 vs. GR 0.05 ± 0.01; Igf-Ir: DM 0.97 ± 0.1 vs. 
GR 0.64 ± 0.06; Igfbp2: DM 1.14 ± 0.32 vs. GR 0.43 ± 0.05, 
all p ≤ 0.05, Fig. 2e). This also was associated with higher 
expression of genes associated with protein degradation 
such as Mafbx and Musa1 (Mafbx: DM 0.7 ± 0.14 vs. GR 
0.93 ± 0.27; Musa1: DM 0.74 ± 0.1 vs. GR 1.09 ± 0.13, all 
p ≤ 0.05, Fig. 2e). No changes were observed in gene expres-
sion of Igf-II, Igf-IIr, Mtor, Tnf-α, Tnfrsflb, Myostatin, Murf, 
Fox01, Fox03, Nf-kb, p53 or Sirt1 (data not shown). Resvera-
trol did not prevent the reductions in myotube growth in GR 
conditions, however importantly, resveratrol administration 
was able to promote significant increases in myotube hyper-
trophy at 72 h when added to existing myotubes after 7 days 
of differentiation in DM conditions (DM; 3785 ± 2542 vs. 
DM RES 4088 ± 2728 μm2, p = 0.05, Fig. 2f, h). This cor-
responded with significant increases in the expression of 
genes associated with myotube hypertrophy such as Igf-I 
(DM; 1.61 ± 0.40 vs. DM RES; 2.12 ± 0.20, p = 0.033; 
Fig. 2i) (with no change in Igf-Ir, IGF-II, Igf-IIr, or Mtor) 
and Myhc7, that codes for the slow type I Myhc protein iso-
form (DM; 3.08 ± 0.81 vs. DM RES; 4.20 ± 0.82, p = 0.002, 
Fig. 2i). Resveratrol however, did not affect expression of 
genes associated with myotube atrophy/protein degradation 
(Tnf-α, Tnfrsf1b, Myostatin, Murf, Mafbx, Musa1, Fox-01, 
3, Nf-kb, p53, data not shown) in this condition. Alterna-
tively, EX-527 treatment (100 nM) also reduced myotube 
number, an observation that approached significance (DM 
9.00 ± 2.59 vs. DM EX-527 5.62 ± 2.94, p = 0.073, Fig. 2g), 
and myotube area at 72 h (DM 3785 ± 2542 vs. DM EX-527; 
3433 ± 2394 μM2, p = 0.026, Fig. 2h). Indeed, the loss of 
myotube number with EX-527 administration at 72 h in 
high-glucose conditions was similar to the loss observed 
in GR conditions alone, confirmed by no significant dif-
ference between these conditions (DM EX-527 5.62 ± 2.94 
vs. GR 5.38 ± 2.28, p = N.S.) and both GR and DM EX-527 
Fig. 2  Loss of myotubes and reduced myotube growth occurred when 
existing myotubes were placed in Glucose Restriction (GR) condi-
tions for 72  h, demonstrated a morphologically and via reductions 
in b myotube number, c myotube diameter and d myotube area. This 
corresponded with reductions in gene expression of myotube matu-
ration genes e Myhc1, 2, 4, 7, reductions in genes associated with 
myofibre hypertrophy Igf-I, Igf-Ir and Igfbp2 and increased expres-
sion of genes associated with myotube atrophy/protein degradation, 
Mafbx and Musa1. Resveratrol was unable to improve myotube sur-
vival or reduced myotube growth in GR conditions at 72 h however, 
resveratrol evoked increases in f, h myotube area at 72 h when glu-
cose was more readily available (DM/differentiation media control 
conditions). This was associated with increases in i Igf-I and Myhc7 
that codes for the slow type I Myhc protein isoform. EX-527 treat-
ment also reduced g myotube number and h myotube area. This was 
associated with reductions in gene expression of j Myhc 1, 2 and 4 
coding for intermediate and IIx, IIa and IIb MYHC protein isoforms, 
respectively. It is worth noting EX-527 administration evoked a simi-
lar 65–68% loss of myotubes experienced in GR conditions alone. 
*Significantly different (p ≤ 0.05) versus DM 72-h conditions. All 
experiments are at least n = 3 in duplicate
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conditions exhibited a similar ~ 65% reduction in myotubes 
vs. 0 h controls (0 h, 8.25 ± 2.85 vs. DM EX-527 5.62 ± 2.94 
(65% reduction) vs. GR 5.38 ± 2.28 (68% reduction), both 
comparisons p ≤ 0.001, Fig. 2g). In these conditions where 
EX-527 was administered yet glucose was more readily 
available, there were also reductions in gene expression of 
Myhc 1, 2 and 4 coding for intermediate/faster IIx, IIa and 
IIb protein isoforms, respectively, (Myhc1; DM 3.39 ± 1.38 
vs. DM EX-527 2.26 ± 0.69, p = 0.09: Myhc2; DM 
1.86 ± 0.41 vs. DM EX-527 1.55 ± 0.08, p = 0.034: Myhc4; 
DM 4.52 ± 2.83 vs. DM EX-527 2.72 ± 0.74, p = 0.058 
(Fig. 2i). Overall, these data suggest that where glucose was 
readily available, resveratrol and EX-527 promoted myotube 
hypertrophy and reduced growth, respectively. Furthermore, 
resveratrol administration regulated Myhc genes towards a 
‘slower’ fibre-type expression profile vs. a reduced interme-
diate/faster expression profile in the presence of EX-527. 
Finally, in these conditions, EX-527 administration evoked 
a similar 65% loss of myotubes, also experienced in GR 
conditions alone.
Resveratrol administration acutely negated reduced 
myotube growth during glucose restriction
Importantly, resveratrol treatment in existing myotubes 
under GR conditions for 24 h was also able to improve 
myotube hypertrophy (Fig. 3a) demonstrated by significant 
improvements in myotube area (GR 2635.30 ± 1524.10 vs. 
GR RES: 3474.00 ± 2235.00 μM2, p < 0.001, Fig. 3b). How-
ever, this was without changes in Myhc gene expression pro-
files as observed above in DM conditions (data not shown). 
Despite this improvement after 24 h, resveratrol was unable 
to improve myotube size in GR conditions at 72 h when 
administered to existing myotubes (data not shown). There-
fore, a single dose of resveratrol had a role in acutely (for 
24 h) negating the effect of reduced myotube growth in vitro 
when modelling interstitial glucose levels of CR in vivo. 
Finally, because of the improvements in myotube size over 
an acute 24-h period with resveratrol treatment in GR condi-
tions yet without alterations in gene expression of myosin 
heavy chains, alterations in more acutely and transiently 
regulated cell signalling activity of energy-sensing protein 
(AMPK) and protein translation initiator (P70S6K) were 
assessed at 15, 30 min, 2 and 24 h in GR and DM condi-
tions in the absence and presence of resveratrol and EX-527. 
Indeed, it has previously been shown that AMPK increases 
following starvation and suppresses activity of protein syn-
thetic signalling (P70S6K) [24]. Resveratrol did not alter the 
activity of energy-dependent sensing protein AMPK or pro-
tein translation initiator P70S6K in glucose-restricted condi-
tions (data not shown). However, EX-527 administration on 
average increased (approaching significance) AMPK phos-
phorylation at 30 min in DM glucose conditions (30 min; 
DM 1.00 ± 0.63 vs. DM EX-527 2.63 ± 1.66, p = 0.066, 2 h 
DM vs. DM EX-527: 1.00 ± 0.36 vs. 2.24 ± 1.45, p = 0.086) 
and 24 h (DM vs. DM EX-527: 1.00 ± 0.43 vs. 2.61 ± 0.75, 
p = 0.069; Fig. 4a, b). Increases in AMPK with EX-527 in 
DM glucose conditions also led to a non-significant reduc-
tion in protein activity of P70S6K at 30 min versus DM 
alone (DM vs. DM EX-527: 1.00 ± 0.56 vs. 0.76 ± 0.15, 
p = N.S). However, similar non-significant reductions were 
observed with resveratrol treatment. Overall, these signal-
ling data perhaps suggest that adequate Sirtuin activity is 
required to enable normal AMPK signalling with normal 
glucose availability; however, resveratrol did not increase 
P70S6K signalling in either GR or DM conditions.
Summary/discussion
In the present study, we hypothesised that resveratrol treat-
ment in skeletal muscle cells would attenuate loss of dif-
ferentiation and reduced myotube size in both regenerat-
ing myoblasts and existing mature myotubes, respectively, 
Fig. 3  Resveratrol was able to 
improve a, b myotube area for 
a period of 24 h after dosing in 
Glucose Restriction (GR) condi-
tions. *Significantly different 
(p ≤ 0.05) versus GR conditions 
alone. All experiments are at 
least n = 3 in duplicate
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during glucose restriction. This hypothesis however was 
partly rejected because, despite confirming increased SIRT1 
phosphorylation with resveratrol administration in DM con-
ditions, we were unable to prevent the block on differentia-
tion in myoblasts caused by GR conditions in the presence 
of resveratrol (10 µM). Importantly however, resveratrol was 
able to evoke increases in myotube area of differentiating 
myoblasts under DM glucose conditions with corresponding 
increases in both Myhc7 and 4 coding for the both slow type 
I and fast IIb Myhc protein isoforms, respectively. Our origi-
nal hypothesis however could be partly accepted in experi-
ments undertaken at more acute time points in mature myo-
tubes. Resveratrol treatment in mature myotubes under GR 
conditions was able to improve myotube hypertrophy over 
an acute 24-h period, but not over 48–72 h. However, this 
observation was without changes in Myhc gene expression 
profiles as previously observed in DM conditions where glu-
cose was available with resveratrol treatment. This suggested 
that a single dose of resveratrol played a role in acutely (for 
24 h) negating the effect of reduced myotube growth when 
modelling in vitro interstitial glucose-restricted levels dur-
ing CR in vivo. Despite this, resveratrol did not appear to 
modulate phosphorylation of energy-sensing protein AMPK 
or protein translation initiator P70S6K in these myotubes. 
EX-527 (SIRT1 inhibitor) administration did however, 
increase average AMPK phosphorylation in both GR and 
DM (that approached significance) glucose conditions with 
a corresponding average, yet non-significant suppression of 
P70S6K in DM glucose conditions. Finally, in myotubes at 
later time points (72 h) where glucose was readily available, 
resveratrol treatment promoted myotube hypertrophy and 
regulated Myhc7 genes towards ‘slower’ fibre type expres-
sion profiles, with SIRT1 inhibition via EX-527 adminis-
tration also causing a reduction in Myhc 1, 2 and 4 coding 
for intermediate and faster IIx, IIa and IIb protein isoforms, 
respectively.
Previous studies have suggested that total MYHC 
protein and myotube size (diameter) are increased when 
glucose is readily available in the presence of 20 µM res-
veratrol [45]. Other studies have suggested that overex-
pression of SIRT1 in mouse and human skeletal muscle 
cells, impairs differentiation and myosin heavy chain 
production, however, if SIRT1 is decreased then muscle 
cells differentiate prematurely [46, 47]. Furthermore, an 
increase in proliferation, inhibition of p21cip and p27kip 
(cyclin-dependent kinase inhibitors important for cell 
cycle exit in G1 in order to enable myoblast fusion) caused 
a reduction in differentiation following SIRT1 overexpres-
sion in rat myoblasts [48]. These studies would therefore 
somewhat disagree with the present investigation. How-
ever, more recently it has been suggested that a resveratrol 
concentration of 10 µM (the same as the present study) 
increased the percentage of cells in the G1 phase cell 
cycle exit required for myoblast differentiation [33]. The 
present study consolidated the role of increased SIRT1 
phosphorylation in differentiating myoblasts via resvera-
trol treatment when glucose is readily available via the 
regulation of increases in Myhc gene expression (slow and 
fast) and increased myotube size, together with increases 
in slow Myhc gene expression in myotubes. Furthermore, 
SIRT1 inhibition via EX-527 administration resulted in 
reductions in intermediate (in myoblasts) and intermedi-
ate/fast (in myotubes) Myhc gene expression, suggesting 
that normal SIRT1 activity is perhaps required to main-
tain adequate intermediate to fast Myhc gene expression. 
Indeed, previous studies have suggested that transgenic 
overexpression of SIRT1 evokes a slow phenotype in mice 
[49]. Due to this interesting finding, future studies may 
wish to investigate the role of SIRT1 activation/inhibition 
on Nuclear factor of activated T-cells (NFAT) activity in 
skeletal muscle cells. As this transcription factor regulates 
the activation of muscle fibre genes associated with the 
characterization of ‘slow’ and ‘fast’ myofibres [50], and is 
known to be transcriptionally suppressed by SIRT1 [51]. 
Finally, if extrapolating to the potential use of resvera-
trol in elderly populations in vivo to attenuate age-related 
muscle loss (sarcopenia). Sarcopenia is characterised by a 
more predominant loss of type II fibres [52] and therefore 
is a contributing factor to reductions in maximum strength 
with age (reviewed in [53]). Data herein suggest resvera-
trol treatment, although resulting in increased myofibre 
size, these fibres may be slower in fibre composition which 
may not be advantageous in terms of force production, 
Fig. 4  Resveratrol treatment did not alter the activity of energy-
dependent sensing protein AMPK or protein translation initiator 
P70s6K in Glucose Restriction (GR) conditions over 24  h. How-
ever, EX-527 treatment on average increased a, b (approached sig-
nificance) AMPK activity at 30 min and 24 h in DM (differentiation 
media control) conditions (level of significance depicted on Fig. 2b). 
All experiments are at least n = 3
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but perhaps may contribute to improvements in metabolic 
health in vivo [54].
As discussed above, although resveratrol treatment was 
unable to restore blocked differentiation in myoblasts under 
GR conditions, resveratrol was able to improve myotube 
diameter and area in GR compared with GR alone conditions 
in mature myotubes over an acute period of 24 h. However, 
this finding did not continue over the remaining time course 
(48–72 h) where myotubes were then lost (reduced number) 
under GR conditions even in the presence of the resveratrol. 
The improvement in myotube size at 24 h with resveratrol 
in GR conditions were not driven by changes in Myhc gene 
expression, as was the case in control conditions where glu-
cose was more readily available. From these findings, we can 
infer that the reduced myotube growth experienced under 
GR conditions may be attenuated following a single dose 
of resveratrol over a 24-h time period. However, repeated 
doses may be required to maintain myotube hypertrophy 
in vitro over a longer time period under GR conditions. 
Yet, this approach in vivo requires further investigation, 
due to altered pharmacokinetics and high absorption, yet 
low bioavailability through the gut after oral administra-
tion [55]. Due to no changes in Myhc gene expression at an 
acute time point of 24 h in myotubes under GR conditions 
in the presence of resveratrol, yet an increase in myotube 
size was observed; we investigated more acute and transient 
mechanisms of intracellular signalling of protein synthetic 
translation initiator P70S6K at 15, 30 min, 2 and 24 h after 
dosing. Furthermore, because glucose restriction in skeletal 
muscle cells has been shown to increase activity of AMPK 
[47] and can suppress growth-related signalling of P70S6K 
via TSC2 inhibition of mTOR [24], we also investigated 
AMPK signalling at the same time points. Despite this, there 
were no changes in phosphorylation of AMPK or P70S6K 
in GR or DM conditions with resveratrol versus relevant 
control conditions. However, we did observe a trend towards 
increased AMPK following EX-527 administration, which 
approached significance in DM conditions together with 
average but non-significant reduction in P70S6K, where 
in this condition there was a corresponding suppression 
of intermediate/fast Myhc gene expression and myotube 
hypertrophy. Additionally, we observed increased AMPK 
with EX-527 treatment in glucose-restricted conditions in 
comparison with resveratrol conditions, yet the increase 
was not significantly increased versus DM conditions and 
no corresponding changes in P70S6K were observed. These 
data suggest that only SIRT1 inhibition via EX-527 admin-
istration was able to moderately increase AMPK activity in 
both glucose conditions. Therefore, normal SIRT1 activity 
may be required for adequate AMPK activity to prevent the 
suppression of P70S6K and the corresponding reductions 
in myotube size observed in SIRT1 inhibitor conditions. 
Despite this, the mechanisms responsible for the increased 
myotube hypertrophy following resveratrol administration at 
24 h in GR conditions were not attributable to alterations in 
energy sensing signalling and/or protein synthetic signalling. 
Indeed, previous literature has suggested that SIRT1 activa-
tion in myoblasts has been shown to inhibit Akt and leucine 
evoked increases in mTOR [56]. Alternatively, SIRT1 and 
2 have also been previously shown to deacetylate mTOR 
at Thr-389 with acetylation blocking P70S6K activation 
and, therefore, deacetylation; resulting in phosphorylation 
of P70S6K [57]. Furthermore, albeit in cardiac muscle, 
SIRT1 has been shown to deacetylate Akt and PDK which 
allows binding to phosphatidylinositol 3,4,5-trisphosphate 
(PIP(3)), its relocation to the membrane where PDK ena-
bles Akt phosphorylation upstream of P70S6K [58]. These 
later studies are in contrast in the present study where we 
found no effect of manipulating SIRT activation (assessed by 
phosphorylation) via resveratrol on P70S6K activity. How-
ever, the present study did not assess SIRT1’s deacetylation 
function, and while phosphorylation of SIRT1 is required to 
enable increases in deacetylase activity [41], this warrants 
further investigation. The present study extends the work 
above by including inhibition of SIRT1 phosphorylation 
by EX-527, which suggests that normal SIRT1 activity was 
required to enable adequate AMPK signalling.
Conclusion
We originally hypothesised that resveratrol treatment 
would improve differentiation and myotube hypertrophy in 
differentiating myoblasts, and prevent myotube atrophy in 
mature differentiated myotubes during glucose restriction 
(GR). Resveratrol treatment did not improve myoblast dif-
ferentiation in GR conditions; however, improved hyper-
trophy of mature myotubes when glucose was available via 
regulation of slow Mhyc gene expression and acutely (for 
24 h) maintained myotube size when modelling interstitial 
low glucose levels mimicking in vivo calorie restriction. 
Repeated administration of resveratrol every 24 h may 
therefore be advantageous in vitro during glucose restric-
tion; however, this requires investigation in mammalian 
models to take into account of altered pharmacokinetics 
and bioavailability in vivo.
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